Both Spero Therapeutics Inc. (NASDAQ:SPRO) and CRISPR Therapeutics AG (NASDAQ:CRSP) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spero Therapeutics Inc. | 11 | -0.15 | 12.36M | -2.18 | 0.00 |
| CRISPR Therapeutics AG | 56 | 0.00 | 34.37M | -3.74 | 0.00 |
In table 1 we can see Spero Therapeutics Inc. and CRISPR Therapeutics AG’s gross revenue, earnings per share and valuation.
Profitability
Table 2 shows the return on equity, return on assets and net margins of the two firms.
| Net Margins | Return on Equity | Return on Assets | |
| Spero Therapeutics Inc. | 114,127,423.82% | -34.5% | -31.2% |
| CRISPR Therapeutics AG | 61,805,430.68% | -50.9% | -39.8% |
Liquidity
Spero Therapeutics Inc.’s Current Ratio is 17.5 while its Quick Ratio is 17.5. On the competitive side is, CRISPR Therapeutics AG which has a 15.8 Current Ratio and a 15.8 Quick Ratio. Spero Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to CRISPR Therapeutics AG.
Analyst Ratings
In next table is delivered Spero Therapeutics Inc. and CRISPR Therapeutics AG’s ratings and recommendations.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Spero Therapeutics Inc. | 0 | 0 | 1 | 3.00 |
| CRISPR Therapeutics AG | 0 | 0 | 4 | 3.00 |
Spero Therapeutics Inc. has a 193.13% upside potential and a consensus price target of $35. Competitively CRISPR Therapeutics AG has a consensus price target of $66.5, with potential downside of -8.11%. Based on the data delivered earlier, Spero Therapeutics Inc. is looking more favorable than CRISPR Therapeutics AG, analysts belief.
Institutional & Insider Ownership
Institutional investors owned 53.1% of Spero Therapeutics Inc. shares and 50% of CRISPR Therapeutics AG shares. Insiders owned roughly 23.71% of Spero Therapeutics Inc.’s shares. Insiders Comparatively, owned 2% of CRISPR Therapeutics AG shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Spero Therapeutics Inc. | -0.95% | -11.87% | -4.77% | 9.14% | -5.63% | 68.94% |
| CRISPR Therapeutics AG | 3.15% | 6.25% | 30.58% | 57.23% | 7.51% | 77.42% |
For the past year Spero Therapeutics Inc. has weaker performance than CRISPR Therapeutics AG
Summary
Spero Therapeutics Inc. beats on 7 of the 11 factors CRISPR Therapeutics AG.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
